Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

被引：18

作者：

Bohl, Stephan R. ^{[1
,2
]}

Schmalbrock, Laura K. ^{[1
,3
,4
,5
,6
]}

Bauhuf, Imke ^{[1
]}

Meyer, Tatjana ^{[1
]}

Dolnik, Anna ^{[3
,4
,5
]}

Szyska, Martin ^{[3
,4
,5
]}

Blaette, Tamara J. ^{[3
,4
,5
]}

Knoedler, Sarah ^{[1
]}

Roehner, Linda ^{[1
]}

Miller, Denise ^{[1
]}

Kull, Miriam ^{[1
]}

Langer, Christian ^{[7
]}

Doehner, Hartmut ^{[1
]}

Letai, Anthony ^{[2
]}

Damm, Frederik ^{[3
,4
,5
]}

Heckl, Dirk ^{[8
]}

Bullinger, Lars ^{[3
,4
,5
,6
]}

Kroenke, Jan ^{[1
,3
,4
,5
]}

机构：

[1] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany

[2] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany

[7] Kempten Hosp, Dept Hematol Internal Oncol & Palliat Care, Kempten, Germany

[8] Halle Univ Hosp, Dept Hematol & Oncol, Childrens Hosp, Halle, Germany

来源：

BLOOD ADVANCES | 2021年 / 5卷 / 09期

关键词：

CLONAL EVOLUTION; DNA-DAMAGE; LENALIDOMIDE; MUTATIONS; REPAIR; RELAPSE; PATHWAY; CANCER; CELLS; P53;

D O I：

10.1182/bloodadvances.2020003541

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapsed/ resistant multiple myeloma has been elucidated, the causal relationship between relapse-specific gene mutations and the sensitivity to a given drug in MM has not systematically been evaluated. To determine the functional impact of gene mutations, we performed combined whole-exome sequencing (WES) of longitudinal patient samples with CRISPR-Cas9 drug resistance screens for lenalidomide, bortezomib, dexamethasone, and melphalan. WES of longitudinal samples from 16 MM patients identified a large number of mutations in each patient that were newly acquired or evolved from a small subclone (median 9, range 1-55), including recurrent mutations in TP53, DNAH5, and WSCD2. Focused CRISPR-Cas9 resistance screens against 170 relapse-specific mutations functionally linked 15 of them to drug resistance. These included cereblon E3 ligase complex members for lenalidomide, structural genes PCDHAS and ANKMY2 for dexamethasone, RB1 and CDK2NC for bortezomib, and TP53 for melphalan. In contrast, inactivation of genes involved in the DNA damage repair pathway, including ATM, FANCA, RADS4B, and BRCC3, enhanced susceptibility to cytotoxic chemotherapy. Resistance patterns were highly drug specific with low overlap and highly correlated with the treatment-dependent clonal evolution in patients. The functional association of specific genetic alterations with drug sensitivity will help to personalize treatment of MM in the future.

引用

页码：2391 / 2402

页数：12

共 60 条

[1]

Alexandrov LB, 2013, NATURE, V502, DOI 10.1038/nature12666

[2] Progress and Paradigms in Multiple Myeloma [J].

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5419-5427

[3] Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis [J].

Arends, Christopher Maximilian ;

Galan-Sousa, Joel ;

Hoyer, Kaja ;

Chan, Willy ;

Jaeger, Marten ;

Yoshida, Kenichi ;

Seemann, Ricarda ;

Noerenberg, Daniel ;

Waldhueter, Nils ;

Fleischer-Notter, Helga ;

Christen, Friederike ;

Schmitt, Clemens A. ;

Doerken, Bernd ;

Pelzer, Uwe ;

Sinn, Marianne ;

Zemojtel, Tomasz ;

Ogawa, Seishi ;

Maerdian, Sven ;

Schreiber, Adrian ;

Kunitz, Annegret ;

Krueger, Ulrike ;

Bullinger, Lars ;

Mylonas, Elena ;

Frick, Mareike ;

Damm, Frederik .

LEUKEMIA, 2018, 32 (09) :1908-1919

[4] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma [J].

Binder, M. ;

Rajkumar, S. V. ;

Ketterling, R. P. ;

Greipp, P. T. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Hayman, S. R. ;

Hwa, Y. L. ;

Zeldenrust, S. R. ;

Lust, J. A. ;

Russell, S. J. ;

Leung, N. ;

Kapoor, P. ;

Go, R. S. ;

Gonsalves, W. I. ;

Kyle, R. A. ;

Kumar, S. K. .

BLOOD CANCER JOURNAL, 2017, 7 :e600-e600

[5] Heterogeneity of genomic evolution and mutational profiles in multiple myeloma [J].

Bolli, Niccolo ;

Avet-Loiseau, Herve ;

Wedge, David C. ;

Van Loo, Peter ;

Alexandrov, Ludmil B. ;

Martincorena, Inigo ;

Dawson, Kevin J. ;

Iorio, Francesco ;

Nik-Zainal, Serena ;

Bignell, Graham R. ;

Hinton, Jonathan W. ;

Li, Yilong ;

Tubio, Jose M. C. ;

McLaren, Stuart ;

Meara, Sarah O' ;

Butler, Adam P. ;

Teague, Jon W. ;

Mudie, Laura ;

Anderson, Elizabeth ;

Rashid, Naim ;

Tai, Yu-Tzu ;

Shammas, Masood A. ;

Sperling, Adam S. ;

Fulciniti, Mariateresa ;

Richardson, Paul G. ;

Parmigiani, Giovanni ;

Magrangeas, Florence ;

Minvielle, Stephane ;

Moreau, Philippe ;

Attal, Michel ;

Facon, Thierry ;

Futreal, P. Andrew ;

Anderson, Kenneth C. ;

Campbell, Peter J. ;

Munshi, Nikhil C. .

NATURE COMMUNICATIONS, 2014, 5

[6] ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies [J].

Botrugno, Oronza A. ;

Bianchessi, Silvia ;

Zambroni, Desiree ;

Frenquelli, Michela ;

Belloni, Daniela ;

Bongiovanni, Lucia ;

Girlanda, Stefania ;

Di Terlizzi, Simona ;

Ferrarini, Marina ;

Ferrero, Elisabetta ;

Ponzoni, Maurilio ;

Marcatti, Magda ;

Tonon, Giovanni .

HAEMATOLOGICA, 2020, 105 (10) :2448-2456

[7] DNA Damage Repair Deficiency in Prostate Cancer [J].

Burdak-Rothkamm, Susanne ;

Mansour, Wael Y. ;

Rothkamm, Kai .

TRENDS IN CANCER, 2020, 6 (11) :974-984

[8] Targeting mutant p53 for efficient cancer therapy [J].

Bykov, Vladimir J. N. ;

Eriksson, Sofi E. ;

Bianchi, Julie ;

Wiman, Klas G. .

NATURE REVIEWS CANCER, 2018, 18 (02) :89-102

[9] Initial genome sequencing and analysis of multiple myeloma [J].

Chapman, Michael A. ;

Lawrence, Michael S. ;

Keats, Jonathan J. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Schinzel, Anna C. ;

Harview, Christina L. ;

Brunet, Jean-Philippe ;

Ahmann, Gregory J. ;

Adli, Mazhar ;

Anderson, Kenneth C. ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Baker, Angela ;

Bergsagel, P. Leif ;

Bernstein, Bradley E. ;

Drier, Yotam ;

Fonseca, Rafael ;

Gabriel, Stacey B. ;

Hofmeister, Craig C. ;

Jagannath, Sundar ;

Jakubowiak, Andrzej J. ;

Krishnan, Amrita ;

Levy, Joan ;

Liefeld, Ted ;

Lonial, Sagar ;

Mahan, Scott ;

Mfuko, Bunmi ;

Monti, Stefano ;

Perkins, Louise M. ;

Onofrio, Robb ;

Pugh, Trevor J. ;

Rajkumar, S. Vincent ;

Ramos, Alex H. ;

Siegel, David S. ;

Sivachenko, Andrey ;

Stewart, A. Keith ;

Trudel, Suzanne ;

Vij, Ravi ;

Voet, Douglas ;

Winckler, Wendy ;

Zimmerman, Todd ;

Carpten, John ;

Trent, Jeff ;

Hahn, William C. ;

Garraway, Levi A. ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad ;

Golub, Todd R. .

NATURE, 2011, 471 (7339) :467-472

[10] Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker [J].

Chavan, S. S. ;

He, J. ;

Tytarenko, R. ;

Deshpande, S. ;

Patel, P. ;

Bailey, M. ;

Stein, C. K. ;

Stephens, O. ;

Weinhold, N. ;

Petty, N. ;

Steward, D. ;

Rasche, L. ;

Bauer, M. ;

Ashby, C. ;

Peterson, E. ;

Ali, S. ;

Ross, J. ;

Miller, V. A. ;

Stephens, P. ;

Thanendrarajan, S. ;

Schinke, C. ;

Zangari, M. ;

van Rhee, F. ;

Barlogie, B. ;

Mughal, T. I. ;

Davies, F. E. ;

Morgan, G. J. ;

Walker, B. A. .

BLOOD CANCER JOURNAL, 2017, 7 :e535-e535

← 1 2 3 4 5 6 →